Imetelstat
Details of the Drug
- Generic Name:
- Imetelstat
- Drug Type:
- Oligonucleotide telomerase inhibitor
- How the Drug is Given:
Injection, for intravenous use
- Names:
- Rytelo
- Imetelstat
Indications and Usage
Imetelstat is FDA approved for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).
Side effects needing medical attention
Most common adverse reactions including laboratory abnormalities are decreased platelets, decreased white blood cells, decreased neutrophils, increased AST, increased alkaline phosphatase, increased ALT, fatigue, prolonged partial thromboplastin time, arthralgia/myalgia, COVID-19 infections, and headache.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.